-+ 0.00%
-+ 0.00%
-+ 0.00%

Senseonics highlights real-world study of one-year Eversense 365 CGM at ADA 2026

PUBT·06/01/2026 12:06:16
Listen to the news
Senseonics highlights real-world study of one-year Eversense 365 CGM at ADA 2026
  • Senseonics flagged new real-world evidence on its Eversense 365 one-year implantable CGM system slated for presentation at ADA 2026 on June 6.
  • The study is set to describe how the device performed in routine U.S. use, including its impact in open-loop and closed-loop diabetes management.
  • Management also plans to brief analysts at ADA on Eversense 365 commercial progress, including the European launch and Sequel twiist pump integration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9728911) on June 01, 2026, and is solely responsible for the information contained therein.